清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma.

作者
Jason R. Westin,Loretta J. Nastoupil,Luis Fayad,Fredrick B. Hagemeister,Yasuhiro Oki,Francesco Turturro,Sairah Ahmed,Maria Alma Rodriguez,Hun Ju Lee,Raphael Eric Steiner,Ranjit K. Nair,Simrit Parmar,Ken H. Young,Timothy J. McDonnell,Hubert H. Chuang,Michael Richard Green,Sattva Swarup Neelapu,Richard Eric Davis
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (15_suppl): 7508-7508 被引量:8
标识
DOI:10.1200/jco.2019.37.15_suppl.7508
摘要

7508 Background: The non-germinal center (non-GCB) subtype of Diffuse Large B-cell Lymphoma (DLBCL) is associated with inferior outcomes from standard immuno-chemotherapy. The BTK inhibitor ibrutinib (I) and immunomodulatory agent lenalidomide (L) have promising activity in non-GCB DLBCL as single agents, and result in synthetic lethality in non-GCB DLBCL models when combined. In relapsed non-GCB DLBCL, rituximab (R), L and I result in overall response rate (ORR) of 55% (Ramchandren, ASH 2018). We report the final results of RLI prior to chemotherapy in newly diagnosed non-GCB DLBCL patients, an investigator initiated, single-arm, open-label, phase 2 study. Methods: Adult patients with non-GCB DLBCL, determined by the Hans method, with adequate organ function and performance status were eligible. The primary objectives were to determine (1A) the ORR of two cycles of RLI as initial therapy, and (1B) the complete response rate (CRR) after 6 cycles of chemotherapy combined with RLI. All patients were treated with rituximab 375 mg/m2 IV day 1, ibrutinib 560 mg po daily, and lenalidomide 25 mg po days 1-10 of 21 day cycles for 2 cycles, followed by 6 additional cycles of RLI with chemotherapy. Results: The protocol accrued 60 patients from May 2016 – February 2019, with 52 patients evaluable for disease response (2 withdrew consent prior to restaging, 6 pending restaging prior to abstract deadline). The median age was 64 years (range: 30-83), 28% were ≥ 70 years, and 50% were female. Half the patients had poor risk IPI, 61% had advanced stage, and 71% had a Ki-67 of ≥ 80%. One patient had a fatal fungal infection (CNS aspergillosis) attributed to high dose corticosteroids and RLI, leading to prohibition of corticosteroids during the RLI only cycles with no further fungal infections identified. The ORR for 2 cycles of RLI was 84.6% (n=44), and the CRR was 38.5% (n=20). One patient refused to proceed with the pre-planned chemotherapy after achieving a CR with 2 cycles of RLI, and remains relapse free 18 months later. Conclusions: The Smart Start trial demonstrates the chemotherapy-free combination of rituximab 375 mg/m2, ibrutinib 560 mg, and lenalidomide 25 mg is highly effective in patients with newly diagnosed non-GCB DLBCL. Additional studies evaluating more cycles of RLI with less chemotherapy consolidation are planned. Clinical trial information: NCT02636322.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
稳重傲柔完成签到,获得积分10
3秒前
byron完成签到 ,获得积分0
4秒前
hy发布了新的文献求助10
4秒前
bae完成签到 ,获得积分10
8秒前
煲汤的螃蟹完成签到 ,获得积分10
17秒前
yinyin完成签到 ,获得积分10
20秒前
songrui643完成签到 ,获得积分10
20秒前
纲纲迅毙了完成签到,获得积分10
21秒前
复杂鸵鸟完成签到,获得积分10
27秒前
浮生若梦完成签到,获得积分10
28秒前
40秒前
eagletyr完成签到 ,获得积分10
40秒前
笔墨纸砚完成签到 ,获得积分10
40秒前
光亮的幻桃完成签到,获得积分10
50秒前
59秒前
hy完成签到,获得积分10
1分钟前
nano完成签到 ,获得积分10
1分钟前
RZH发布了新的文献求助10
1分钟前
机智的如曼完成签到,获得积分10
1分钟前
Xzx1995完成签到 ,获得积分10
1分钟前
FashionBoy的应助被科研通管家采纳,获得10
1分钟前
fairytaler的应助被科研通管家采纳,获得10
1分钟前
现代的初之完成签到,获得积分10
1分钟前
大模型的应助被蜗牛好好飞采纳,获得10
1分钟前
ChatGPT完成签到,获得积分10
1分钟前
慕青的应助被蜗牛好好飞采纳,获得10
1分钟前
夏同学完成签到 ,获得积分10
1分钟前
今后的应助被蜗牛好好飞采纳,获得10
1分钟前
wwrjj完成签到,获得积分0
1分钟前
搜集达人的应助被cc采纳,获得10
1分钟前
大模型的应助被蜗牛好好飞采纳,获得10
1分钟前
2分钟前
2分钟前
御坂10576号完成签到,获得积分10
2分钟前
2分钟前
义气的雅琴完成签到,获得积分10
2分钟前
cc发布了新的文献求助10
2分钟前
NexusExplorer的应助被蜗牛好好飞采纳,获得10
2分钟前
Harlotte完成签到 ,获得积分0
2分钟前
蒋不惜完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697